Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
33
NNVC Quote, Financials, Valuation and Earnings
Last price:
$1.21
Seasonality move
:
35.28%
Day range:
$1.22 - $1.27
52-week range:
$0.94 - $2.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.11x
Volume:
121.9K
Avg. volume:
316.8K
1-year change:
-18.95%
Market cap:
$22.3M
Revenue:
--
EPS (TTM):
-$0.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-- | -$0.19 | -100% | -12.44% | $5.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NNVC
NanoViricides, Inc.
|
$1.24 | $6.50 | $22.3M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
$1.46 | $5.00 | $45.5M | -- | $0.00 | 0% | 506.07x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$10.64 | $0.85 | $1.3B | 17.87x | $0.80 | 0% | 20.67x |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $724.3K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NNVC
NanoViricides, Inc.
|
-- | 0.780 | -- | 0.95x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
7.66% | -2.827 | 2.29% | 7.81x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-$116K | -$5.7M | -126.64% | -133.63% | -6324.44% | -$6.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
NanoViricides, Inc. vs. Competitors
-
Which has Higher Returns NNVC or ATNM?
Actinium Pharmaceuticals, Inc. has a net margin of -- compared to NanoViricides, Inc.'s net margin of -5701.11%. NanoViricides, Inc.'s return on equity of -92.29% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.
Company Gross Margin Earnings Per Share Invested Capital NNVCNanoViricides, Inc.-- -$0.10 $7.2M ATNMActinium Pharmaceuticals, Inc.-128.89% -$0.16 $14.9M -
What do Analysts Say About NNVC or ATNM?
NanoViricides, Inc. has a consensus price target of $6.50, signalling upside risk potential of 424.19%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 242.47%. Given that NanoViricides, Inc. has higher upside potential than Actinium Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than Actinium Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NNVCNanoViricides, Inc.1 0 0 ATNMActinium Pharmaceuticals, Inc.3 1 0 -
Is NNVC or ATNM More Risky?
NanoViricides, Inc. has a beta of 1.234, which suggesting that the stock is 23.439% more volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.303, suggesting its less volatile than the S&P 500 by 130.258%.
-
Which is a Better Dividend Stock NNVC or ATNM?
NanoViricides, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoViricides, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NNVC or ATNM?
NanoViricides, Inc. quarterly revenues are --, which are smaller than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. NanoViricides, Inc.'s net income of -$1.8M is higher than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, NanoViricides, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoViricides, Inc. is -- versus 506.07x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NNVCNanoViricides, Inc.-- -- -- -$1.8M ATNMActinium Pharmaceuticals, Inc.506.07x -- $90K -$5.1M
-
Which has Higher Returns NNVC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to NanoViricides, Inc.'s net margin of -255.85%. NanoViricides, Inc.'s return on equity of -92.29% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital NNVCNanoViricides, Inc.-- -$0.10 $7.2M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About NNVC or NBY?
NanoViricides, Inc. has a consensus price target of $6.50, signalling upside risk potential of 424.19%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -92.01%. Given that NanoViricides, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NNVCNanoViricides, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is NNVC or NBY More Risky?
NanoViricides, Inc. has a beta of 1.234, which suggesting that the stock is 23.439% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock NNVC or NBY?
NanoViricides, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. NanoViricides, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NNVC or NBY?
NanoViricides, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. NanoViricides, Inc.'s net income of -$1.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, NanoViricides, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 17.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoViricides, Inc. is -- versus 20.67x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NNVCNanoViricides, Inc.-- -- -- -$1.8M NBYNovaBay Pharmaceuticals, Inc.20.67x 17.87x $521K -$1.3M
-
Which has Higher Returns NNVC or OGEN?
Oragenics, Inc. has a net margin of -- compared to NanoViricides, Inc.'s net margin of --. NanoViricides, Inc.'s return on equity of -92.29% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital NNVCNanoViricides, Inc.-- -$0.10 $7.2M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About NNVC or OGEN?
NanoViricides, Inc. has a consensus price target of $6.50, signalling upside risk potential of 424.19%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.22%. Given that NanoViricides, Inc. has higher upside potential than Oragenics, Inc., analysts believe NanoViricides, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NNVCNanoViricides, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is NNVC or OGEN More Risky?
NanoViricides, Inc. has a beta of 1.234, which suggesting that the stock is 23.439% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock NNVC or OGEN?
NanoViricides, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoViricides, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NNVC or OGEN?
NanoViricides, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. NanoViricides, Inc.'s net income of -$1.8M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, NanoViricides, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoViricides, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NNVCNanoViricides, Inc.-- -- -- -$1.8M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns NNVC or PTN?
Palatin Technologies has a net margin of -- compared to NanoViricides, Inc.'s net margin of --. NanoViricides, Inc.'s return on equity of -92.29% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NNVCNanoViricides, Inc.-- -$0.10 $7.2M PTNPalatin Technologies-- -- -- -
What do Analysts Say About NNVC or PTN?
NanoViricides, Inc. has a consensus price target of $6.50, signalling upside risk potential of 424.19%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than NanoViricides, Inc., analysts believe Palatin Technologies is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NNVCNanoViricides, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is NNVC or PTN More Risky?
NanoViricides, Inc. has a beta of 1.234, which suggesting that the stock is 23.439% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock NNVC or PTN?
NanoViricides, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoViricides, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NNVC or PTN?
NanoViricides, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. NanoViricides, Inc.'s net income of -$1.8M is higher than Palatin Technologies's net income of --. Notably, NanoViricides, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoViricides, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NNVCNanoViricides, Inc.-- -- -- -$1.8M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns NNVC or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to NanoViricides, Inc.'s net margin of --. NanoViricides, Inc.'s return on equity of -92.29% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital NNVCNanoViricides, Inc.-- -$0.10 $7.2M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About NNVC or TOVX?
NanoViricides, Inc. has a consensus price target of $6.50, signalling upside risk potential of 424.19%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3043.24%. Given that Theriva Biologics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Theriva Biologics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NNVCNanoViricides, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is NNVC or TOVX More Risky?
NanoViricides, Inc. has a beta of 1.234, which suggesting that the stock is 23.439% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock NNVC or TOVX?
NanoViricides, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NanoViricides, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NNVC or TOVX?
NanoViricides, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. NanoViricides, Inc.'s net income of -$1.8M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, NanoViricides, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NanoViricides, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NNVCNanoViricides, Inc.-- -- -- -$1.8M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
70
RGC alert for Jan 8
Regencell Bioscience Holdings Ltd. [RGC] is down 21.5% over the past day.
Buy
64
RVMD alert for Jan 8
Revolution Medicines, Inc. [RVMD] is up 4.61% over the past day.
Sell
38
CRNX alert for Jan 8
Crinetics Pharmaceuticals, Inc. [CRNX] is down 0.23% over the past day.
